Subject: Somatogen And Questions Over Blood Product 
Date: Published: 9/8/92 (30 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    OTC Focus:
    Somatogen Shares Look Risky to Some,
    Who Cite Questions Over Blood Product
    ----
    By Sara Calian
    Staff Reporter of The Wall Street Journal

    NEW YORK -- Fallen from the biotech pedestal and trading below
 last year's initial offering price, Somatogen Inc. still looks to
 many investors like too risky a proposition.
    This once-hot stock bottomed at 15 1/4 recently, seemingly a
 bargain compared with the 30 prevailing two months ago.  Bulls shrug
 off the reason for the stock's slide, namely recent news of slight
 side effects associated with the company's main product.  By Friday
 the stock had edged up to 17 3/8, still below the IPO price of 19 a
 year ago.
    Somatogen has grand plans.  It aspires to develop a cheap and pure
 substitute for oxygen-carrying components of human blood that can be
 used for surgery patients and accident victims.  The Boulder, Colo.,
 company is vying for a leading position in what some analysts say
 could be a $2 billion to $5 billion-a-year market sparked by the
 threat of AIDS and other diseases in tainted blood.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]